Type 2 Diabetes Market Trends, Challenges and Growth Drivers Analysis 2020 adds Global Type 2 Diabetes Market 2016-2020 a new research reports in its store. The analysts forecast global type 2 diabetes drugs market to grow at a CAGR of 7.28% during the period 2016-2020.

Commenting on the report, an analyst said: "The growing awareness of type 2 diabetes and the treatments available for it, as a result of national and global initiatives, drives the market. The increase in the diabetic population has increased accessibility to disease monitoring and disease management devices, and key vendors have begun to focus on emerging markets such as China."

According to the report, obesity, unhealthy diets, and lack of physical activity have increased the number of diabetes cases worldwide. As reported by WHO, it was estimated that 9% of the adults who are 18 years and above had diabetes in 2014. It was also reported that the global prevalence of diabetes would be around 366 million by 2030. In 2013, nearly 21 million live births were affected by diabetes during pregnancy. An increase in the exposure to the risk factors for type 2 diabetes in low- and middle-income groups is increasing in Middle East, North Africa, Southeast Asian, and Western Pacific regions.

Inquire for more details @ .

Further, the report states that low diagnosis rate impedes people from availing the treatment, posing a challenge for the market.

Key players in the Global Type 2 Diabetes Market: AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, and Sanofi SA. Other Prominent Vendors in the market are: Adocia, Akros Pharma, Amgen, Astellas Pharma, Biocon, Boehringer Ingelheim, Chipscreen Biosciences, ConjuChem, CymaBay Therapeutics, Daiichi Sankyo, DiaMedica, Diasome Pharmaceuticals, Dong-A ST, Elcelyx Therapeutics, Exsulin, Generex, Genfit, Hanmi, Hua Medicine, InteKrin Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Japan Tobacco, Kadmon, KinDex Pharmaceuticals, Kissei, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Ligand, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Novartis, NGM Bio, NuSirt Biopharma, Oramed, Peptron, Pfizer, PhaseBio, Poxel, Sanwa Kagaku Kenkyusho, Sirona Biochem, Takeda, Theracos, Theratechnologies, Transition Therapeutics, VeroScience, vTv Therapeutics, and XBiotech.

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Purchase a copy of Global Type 2 Diabetes Market 2016-2020 report @ for US $2500.

Table of Content for Global Type 2 Diabetes Market 2016-2020:

PART 01: Executive summary

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights
Key buying criteria

PART 05: Disease overview
Risk factors
Economic burden

PART 06: Pipeline portfolio

PART 07: Market landscape
Global diabetes drugs market
Global type 2 diabetes drugs market
Five forces analysis

PART 08: Market segmentation by drug class

PART 09: Insulin
Product portfolio
Global insulin market

PART 10: DPP-4 inhibitors
Market overview
Market size and forecast

PART 11: GLP-1 receptor agonists
Market overview
Market size and forecast

PART 12: SGLT-2 inhibitors
Market overview
Market size and forecast

PART 13: Geographical segmentation
Global type 2 diabetes drugs market by geographical segmentation 2015-2020
Type 2 diabetes drugs market in Americas
Type 2 diabetes drugs market in EMEA
Type 2 diabetes drugs market in APAC

PART 14: Market drivers
Rising prevalence of diabetes
Rise in obesity rates
Growing older population
Unmet medical needs
Stringent regulatory guidelines for biosimilar drugs

PART 15: Impact of drivers

PART 16: Market challenges
Low diagnosis rate
Rising concerns in scientific community
Gaps in national-level diabetes management plans
Poor storage conditions and distribution policies for insulin
Fierce market competition

PART 17: Impact of drivers and challenges

PART 18: Market trends
Increase in awareness of diabetes
Increase in academia-industry collaboration
Rising price of diabetes drugs
Increase in R&D

PART 19: Vendor landscape
Competitive scenario
Market analysis 2015
Novo Nordisk
Eli Lilly
Other prominent vendors

PART 20: Appendix0
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for type 2 diabetes drugs
Exhibit 03: Line of therapy for type 2 diabetes
Exhibit 04: Pipeline portfolio: Global type 2 diabetes drugs market
Exhibit 05: Global diabetes drugs market by prevalence based on type of disease 2015
Exhibit 06: Top selling diabetes drugs based on sales 2014 ($ billions)
Exhibit 07: Market share of global diabetes drugs in global pharmaceutical drugs market 2015
Exhibit 08: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 09: Market share analysis of vendors in global diabetes drugs market
Exhibit 10: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis and more..

Inquire for Discount @

About US:  is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.